COVID-19 and the Liver: A 2021 Update

Catherine W. Spearman; Alessio Aghemo; Luca Valenti; Mark W. Sonderup

Disclosures

Liver International. 2021;41(9):1988-1998. 

In This Article

Approach to Abnormal Liver Enzymes in COVID-19 Patients

Patients admitted to hospital with moderate-to-severe disease should have baseline liver tests including ALT, AST, GGT, ALP and bilirubin. Liver enzymes should be monitored as COVID-19 progresses. The aetiology of deranged liver enzymes is invariably multifactorial in the COVID-19 setting. Acute or chronic viral hepatitis and potential hepatotoxins such as statins, azithromycin, lopinavir/ritonavir, remdesivir, tocilizumab, enoxaparin and paracetamol need to be excluded. A direct cytopathic effect on hepatocytes of SARS-CoV-2 is possible as the virus has been isolated from the liver.[46] Furthermore, mitochondrial proteins may directly interact with the virus, which may explain the frequent AST predominance observed.[50] Lastly, the pro-inflammatory response enabling the cytokine storm (IL-2, IL-6, IL-7, GM-CSF, IP-10, MCP-1, MIP-1α, TNF-α) further exacerbated by intrahepatic cytotoxic T cells and Kupffer cell activation contributes to liver enzyme derangement. Myocarditis or skeletal muscle myositis can accentuate the AST levels and warrants consideration in those with disproportionately elevated AST levels.

processing....